CNS Pharmaceuticals, Inc.
NASDAQ:CNSP
1.14 (USD) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.004 | 0.012 | 0.013 | 0.011 | 0.002 | 0 | 0 |
| Gross Profit
| 0 | -0.004 | -0.012 | -0.013 | -0.011 | -0.002 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 9.29 | 14.096 | 9.3 | 9.346 | 5.062 | 1.854 | 0.021 | 0.033 |
| General & Administrative Expenses
| 5.612 | 4.77 | 5.967 | 4.681 | 4.393 | 1.979 | 0.861 | 0.438 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.255 |
| SG&A
| 5.612 | 4.77 | 5.967 | 4.681 | 4.393 | 1.979 | 0.861 | 0.182 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | -6.463 | 0 |
| Operating Expenses
| 14.902 | 18.865 | 15.267 | 14.027 | 9.455 | 3.833 | 0.882 | 0.215 |
| Operating Income
| -14.902 | -18.865 | -15.267 | -14.027 | -9.455 | -3.833 | -0.882 | -0.215 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.044 | 0.014 | -0.007 | -0.009 | -0.003 | -0.044 | -6.51 | -0.004 |
| Income Before Tax
| -14.858 | -18.851 | -15.274 | -14.037 | -9.458 | -3.877 | -7.392 | -0.219 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0.007 | 0.009 | 0.003 | 0.042 | 0.047 | -0.516 |
| Net Income
| -14.858 | -18.851 | -15.274 | -14.495 | -9.458 | -3.877 | -7.392 | -0.526 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -38.87 | -251.35 | -560.83 | -852.66 | -859.81 | -353.57 | -674.07 | -48.01 |
| EPS Diluted
| -38.87 | -250.19 | -560.83 | -825.04 | -853.68 | -353.57 | -674.07 | -48.01 |
| EBITDA
| -14.902 | -18.861 | -15.255 | -14.473 | -9.444 | -3.831 | -6.463 | 0 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |